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DNA hypermethylation and 
differential gene expression 
associated with Klinefelter 
syndrome
Anne Skakkebæk1,2,3, Morten Muhlig Nielsen3, Christian Trolle1, Søren Vang3, 
Henrik Hornshøj3, Jakob Hedegaard3, Mikkel Wallentin4,5, Anders Bojesen2, 
Jens Michael Hertz6, Jens Fedder7, John Rosendahl Østergaard8, Jakob Skou Pedersen  3,9 & 
Claus Højbjerg Gravholt  1,3
Klinefelter syndrome (KS) has a prevalence ranging from 85 to 250 per 100.000 newborn boys making 
it the most frequent sex chromosome aneuploidy in the general population. The molecular basis for the 
phenotypic traits and morbidity in KS are not clarified. We performed genome-wide DNA methylation 
profiling of leucocytes from peripheral blood samples from 67 KS patients, 67 male controls and 33 
female controls, in addition to genome-wide RNA-sequencing profiling in a subset of 9 KS patients, 9 
control males and 13 female controls. Characterization of the methylome as well as the transcriptome 
of both coding and non-coding genes identified a unique epigenetic and genetic landscape of both 
autosomal chromosomes as well as the X chromosome in KS. A subset of genes show significant 
correlation between methylation values and expression values. Gene set enrichment analysis of 
differentially methylated positions yielded terms associated with well-known comorbidities seen in 
KS. In addition, differentially expressed genes revealed enrichment for genes involved in the immune 
system, wnt-signaling pathway and neuron development. Based on our data we point towards new 
candidate genes, which may be implicated in the phenotype and further point towards non-coding 
genes, which may be involved in X chromosome inactivation in KS.
Klinefelter syndrome (KS; 47,XXY) has a prevalence ranging from 85 to 250 per 100.000 liveborn males making 
it the most frequent sex chromosome aneuploidy in the general population1. Ethnic differences in the prevalence 
of KS may exist1. The presence of the additional X chromosome is associated with a number of health prob-
lems involving multiple organs and consequently are both morbidity and mortality significantly increased2,3. 
The increased morbidity seen in KS is due to an increased risk of developing physical diseases such as diabetes, 
metabolic syndrome, obesity, cardiovascular disease, infections, osteoporosis, as well as psychiatric diseases3. In 
addition, many patients with KS suffer from cognitive disabilities and behavioral problems. However, the degree 
of co-morbidity seen between KS patients display great heterogeneity, and as a consequence, diagnosis is often 
delayed4 and thereby also prevention and treatment of associated comorbidities.
To date, the only gene associated with the KS phenotype is SHOX5. It is localized in the pseudoautosomal 
region of the sex chromosomes and likely causes the tall stature in KS due to the presence of a third copy5. In 
cells with more than one X chromosome, one of the X chromosome is inactivated6 in order to avoid a potentially 
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toxic double dose of X-linked genes. It has been hypothesized that some phenotypic features seen in KS may be 
explained by an overexpression of the 15% of X chromosomal genes escaping X chromosomal inactivation and 
of the 10% showing a variable cell-type specific expression7–9 due to a dosage effect equal to that seen in female, 
but different from what is normally seen in males. In addition, the hormonal imbalance with hypergonadotropic 
hypogonadism caused by gonadal dysfunction in KS10 has also been linked to some of the co-morbidities seen 
in KS, such as the increased prevalence of diabetes, obesity and metabolic syndrome, osteoporosis and cognitive 
disabilities. Hypogonadism alone, however, cannot explain the entire KS phenotype as hypogonadism often first 
develops during adolescent/adulthood10,11, where many of the co-morbidities are already present. The underlying 
mechanisms, linking the extra X chromosome to the clinical phenotype and the associated co-morbidities seen 
in KS thus remain unexplained.
Recently, a few studies have provided evidence that KS may be associated with widespread changes in the 
methylome of both blood and brain tissue12–14. These genome-wide alterations in DNA methylation may play 
a role in the biological mechanisms underlying the clinical KS phenotype by affecting chromatin structure and 
gene expression and thereby potentially be responsible for the development of phenotypical traits and diseases. 
Interestingly, alterations of the trancriptome in blood, brain tissue and testis tissue in KS13,15–20 have also been 
demonstrated, thereby supporting the hypothesis that sex chromosomes may regulate gene expression through-
out the genome21. However, thus far only one study has investigated the potential association between alterations 
in the methylome and changes in the transcriptome in KS patients however this study were performed on brain 
tissue and included a single KS patient13. In addition, all of the above mentioned methylation studies either were 
performed on small KS cohorts or used arrays with a relative small number of CpG sites. Also, only one of the 
studies assessing RNA expression in KS have included a comprehensive analysis of non-coding RNA in addition 
to coding-RNA19.
To perform a comprehensive characterization of the methylome as well as the transcriptome in KS including 
both coding as well as non-coding genes and to further investigate the association between alteration in the 
methylome and changes in the transcriptome in KS patients, we performed DNA methylation profiling and total 
RNA-Seq transcription profiling in a cohort of KS patients and in female and male controls. Our aim was to 
assess the functional impact of epigenetic alterations on the transcriptome in KS, to enhance the understanding 
of molecular mechanism behind the observed phenotype and the increased risk of comorbidities in addition to 
describe the methylome and transcriptome of KS.
Characterization of the methylome as well as the transcriptome of both coding and non-coding genes identi-
fied a unique epigenetic and genetic landscape in KS, with correlation analysis between the methylome and tran-
scriptome revealing few genes with a direct association. Gene set enrichment analysis based on the methylation 
and expression analysis yielded terms associated with well-known comorbidities seen in KS as well as an affected 
immune system, wnt-signaling pathway and neuron development. Based on our data, we point towards several 
candidate genes, which may be implicated in the phenotype of KS and further point towards ncRNAs, which may 
be involved in X chromosome inactivation in KS and in the regulation of escape genes.
Results
Klinefelter syndrome is associated with a distinct X chromosomal and autosomal DNA meth-
ylation signature. We performed whole-blood genome-wide DNA methylation in 67 males with verified 
KS (47,XXY), 67 male controls (46,XY) and 33 female controls (46,XX) using the 450K-Illumina Infinium assay. 
CpG methylation at autosomal loci as well as at X chromosomal loci clearly differed between KS and controls, 
as reflected by the clear separation of the three groups in principal component analyses (Fig. 1A,B). Comparing 
the methylation level of the CpG sites on the two X chromosomes of KS and female controls, we found 11 dif-
ferentially methylated positions (DMPs) (ten were hypermethylated; one was hypomethylated) (FWER < 0.05; 
absolute delta-M-value > 1) (Fig. 1D, Table 1, Supplementary Table S1) corresponding to eight genes (FUNDC1, 
KDM5C, LOC100132831, MED14, SHROOM2, TAF7L, TFDP3 and XIST). Extending our analysis to the autoso-
mal CpG sites, we identified 168 DMPs (145 hypermethylated; 23 hypomethylated) between KS and male con-
trols (Supplementary Table S2), 1071 DMPs (454 hypermethylated; 617 hypomethylated) between KS and female 
controls and 487 DMPs (325 hypermethylated; 162 hypomethylated) between male and female controls (FWER 
< 0.05; absolute delta-M-value > 1) corresponding to 85, 895 and 425 genes, respectively (Fig. 1C,D, Table 1). 72 
DMPs overlapped between both KS contrasts (Fig. 1C). The distribution of the methylation levels of the hyper- 
and hypomethylated autsomal DMPs (delta-Beta > 0.1) showed almost overlapping normally distributed curves, 
with hypermethylated DMPs having a median beta value of 0.59 and hypomethylated DMPs having a median 
beta value of 0.37 (Fig. 2A).
Differentially methylated regions (DMRs) (i.e. methylation in groups of nearby positions) have been suggested 
to serve a functional role in gene transcriptional regulation22. We therefore extended our methylation analysis 
to the regional level. We identified nine X chromosomal DMRs between KS and female controls, all located to 
genes (FDR < 0.05, absolute delta-M-value > 0.1) (Supplementary Table S3), in addition to 233 autosomal DMRs 
between KS and male controls (171 were located to known genes) and 488 autosomal DMRs between KS and 
female controls (401 were located to known genes) (FDR < 0.05, absolute delta-M-value > 0.1). Of the DMRs 
located to known genes, 73 were common to both KS contrasts (Supplementary Table S4).
Autosomal DMPs relation to CpG island status, genic location and chromosomal location. We 
explored the distribution of autosomal DMPs from the KS vs male controls, and KS vs female controls compar-
ison in relation to CpG island status. Each CpG site of the 450 K Illumina array are annotated according to their 
relation to CpG islands. Six annotation categories exist. These include (1) within a CpG island, (2) north shore 
(within 2 kb upstream of an island), (3) south shore (within 2 kb downstream of an island), (4) north shelf (within 
2–4 kb upstream of an island), (5) south shelf (within 2–4 kb downstream of an island) or 6) sea (none of the 
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above-mentioned locations). We found a significant difference in the distribution of hypermethylated, but not 
hypomethylated DMPs compared to the distribution of all autosomal loci on the array, with hypermethylated 
DMPs enriched inside CpG islands and north shores (Fig. 2B). To further characterize the methylation changes in 
Figure 1. DNA methylation between KS and controls. (A) Principal component analysis plot of the 5000 most 
variable autosomal CpG positions between KS (green), male controls (blue) and female controls (orange). (B) 
Principal component analysis plot of the 100 most variable X chromosomal CpG positions between KS (green) 
and female controls (orange). (C) Venn diagram of autosomal differentially methylated positions with FWER < 
0.05 and absolute delta-M-value > 1. (D) Volcano plots of −log 10 (Familiy Wise Error rate = Bonferroni) against 
delta-M values of differentially methylated positions adjusted for age and relative cell proportion. Orange dots 
are differentially methylated positions with FWER < 0.05 and absolute delta-M-value > 1. Red line represents 
FWER = 0.05. The first three panels represents autosomal DMPs. (E) Manhattan plot of autosomal differentially 
methylated positions between KS and male controls. Blue dots are differentially methylated positions with FWER 
< 0.05 and absolute delta-M-value > 1. Red line represents FWER = 0.05. (F) Manhattan plot of autosomal 
differentially methylated positions between KS and female controls. Blue dots are differentially methylated 
positions with FWER < 0.05 and absolute delta-M-value > 1. Red line represents FWER = 0.05.
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KS, we analyzed DMPs according to their genic location (proximal promotor, distal promotor, gene body, down-
stream and intergenic).Hypergeometric test revealed no enrichment in relation to genic location when comparing 
KS to male controls, however an enrichment was seen in proximal promotors when comparing KS to female 
DNA methylation data
KS vs. Male KS vs. Female Male vs. Female
Hyper Hypo Hyper Hypo Hyper Hypo
DMPs
(FWER < 0.05, absolute delta-M-value > 1) X chr
— — 10 1 — —
145 23 454 617 325 162
RNA-Seq data
KS vs. Male KS vs. Female Male vs. Female
Up Down Up Down Up Down
DEGs
(FDR < 0.05, absolute logFC ≥0.3)
X chr 20 1 28 34 36 51
Autosomal 20 11 620 1182 721 1189
NcRNAs
(FDR < 0.05, absolute logFC ≥0.3)
X chr 7 0 14 22 18 34
Autosomal 6 17 294 503 355 671
Table 1. The number of differentially methylated positions (DMPs), differentially expressed genes (DEGs) and 
differentially expressed non-coding RNAs (ncRNAs) between groups.
Figure 2. Distribution of methylation values and autosomal DMPs. (A) Distribution of methylation values 
(Beta-values) in KS, male controls and female controls. A normal biphasic distribution is seen when including 
all CpG sites, whereas the distribution of hypomethylated and hypermethylated CpG sites are almost normally 
distributed and overlapping. (B) The distribution of autosomal DMPs between KS and male controls in relation 
to CpG island status. Hypermethylated CpG sites are enriched in island and north shores.
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controls. Subsequently, we also analyzed the distribution of autosomal DMPs in relation to chromosomal loca-
tion. As illustrated in Fig. 1E,F, the DMPs were distributed genome wide, including all autosomal chromosomes. 
Hypergeometric test revealing enrichment of chromosome 17, 19 and 22 when comparing KS to male controls 
and enrichment of chromosome 18, 19 and 22 when comparing KS to female controls.
DNA methylation in repetitive elements is not altered in Klinefelter syndrome. About 50% of 
the human genome is accounted for by DNA repetitive elements23. Repetitive elements include transposons, 
which often target protein-coding genes, which can lead to genomic instability and thereby predispose to cancer 
and other diseases24. We therefore wanted to investigate if KS was associated with altered methylation level in 
these repetitive elements compared to male controls. Probes located to repetitive elements (n = 19465) were inves-
tigated and of these 202 were hypermethylated and 79 hypomethylated in KS compared to male controls (FWER 
> 0.05). Only two DMPs, both hypomethylated, reached a FWER > 0.05 and absolute delta-Beta value > 0.1 
(Supplementary Fig. S1). Furthermore, we identified five regions with a FWER > 0.05 and absolute delta-Beta > 
0.1 (Supplementary Fig. S1). Comparing the number of DMPs located in repetitive elements with the number of 
DMPs in the remaining part of the genome revealed no enrichment of DMPs in repetitive elements (p = 0.99).
Differential methylated DMPs associated with co-morbidities in Klinefelter syndrome. In 
order to gain insight into possible biological functions of the methylation changes seen in KS, we annotated auto-
somal DMPs common to both KS contrasts (FWER < 0.05, absolute delta-M-Value > 0.5, n = 305) to genes and 
performed gene set enrichment. Gene-centric modular analysis revealed enrichment for terms related to diabetes, 
obesity, height, coronary and arterial disease, hypercholesterolemia, gingivitis and periodontitis, bone mineral 
density, cancer (breast, prostate, colon, pancreas, leukemia, lymphoma), connective tissue diseases, infection and 
inflammation and others (Supplementary Table S5). Gene-centric modular analysis of X chromosomal DMPs 
between KS and female controls (FWER < 0.05, absolute delta-M-Value > 0.5, n = 43) revealed no enrichment. In 
addition, we used the Genomic Regions Enrichment of Annotation Tool (GREAT) to relate both X chromosomal 
DMRs between KS and female controls (FDR < 0.05, absolute delta-M-value > 0.1, n = 9) as well as autosomal 
DMRs between both contrasts (FDR < 0.05, absolute delta-M-value > 0.1, n = 73) for possible functional signif-
icance. Enrichment analysis of autosomal DMRs revealed enrichment for terms related to obesity, dyslipidemia, 
hypertension, congenital heart anomalies and late fetal loss (Supplementary Table S6). No enrichments were 
found for X chromosomal DMRs.
Differentially expressed coding genes in Klinefelter syndrome. Subsequently, we performed 
RNA-Seq expression profiling in a subset of participants including nine KS, nine male controls and thirteen 
female controls. We found that KS clustered with male controls based on autosomal RNA-Seq data, whereas 
no clear clustering was seen between the three groups based on X chromosomal RNA-Seq data (Figs 3A and 
4A). Although, no clear KS clustering was seen, an analysis of autosomal genes revealed 31 (20 upregulated, 
11 downregulated) differentially expressed genes (DEGs) between KS and male controls and 1,802 DEGs (620 
upregulated, 1,182 downregulated) between KS and female controls with 13 genes differentially expressed in both 
KS contrasts (FDR < 0.05 and absolute logFC ≥0.3) (Fig. 3B,C, Table 1, Supplementary Table S7). In addition, 
we found 1,910 DEGs (721 upregulated, 1,189 downregulated) between male and female controls. X chromo-
somal analysis revealed 21 DEGs (20 upregulated and 1 downregulated) between KS and male controls (Table 1, 
Supplementary Table S8) and 62 DEGs (28 upregulated and 34 downregulated) between KS and female controls, 
with 2 genes (AMOT, SLC25A6) differentially expressed in both KS contrasts (FDR < 0.05; absolute log fold 
change ≥0.3) (Fig. 4B,C, Table 1). 77 DEGs (26 upregulated and 51 downregulated) were found between male 
and female controls (Fig. 4,C, Table 1).
Approximately 15% of X chromosomal genes escape X inactivation in female mammals and additional 10% 
shows a variable cell-type specific inactivation pattern7–9. Genes escaping X chromosomal inactivation have been 
suggested to influence the phenotype seen in KS, due to a dosage effect equal to that seen in female, but different 
from what is normally seen in males. Furthermore, genes located in the pseudoautosomal regions (PAR1 and 
PAR2) of the X and Y chromosomes have been proposed as candidate genes for the phenotypic traits seen in KS, 
due to the extra copy of these genes, compared to the normal two copies. We therefore annotated X chromosomal 
genes to escape (n = 133), inactivated (n = 177) or pseudoautosomal genes (n = 16)21. No clear clustering was 
seen between the three groups based on RNA-Seq data of neither escape, inactivated nor pseudoautosomal genes 
(Supplementary Fig. S5). We identified 10 differentially expressed escape genes between KS and male controls 
(FDR < 0.05; absolute log fold change ≥0.3) (Fig. 4D). One gene (KDM5C) was differentially expressed in both 
KS contrasts; however, upregulated compared to male controls and downregulated compared to female controls 
(Supplementary Fig. S4). For six of the genes (KDM5C, EIF1AX, ZFX, KDM6A, DDX3 X , TXLNG) a Y homolog 
exist. A decreased expression level was found in female controls compared to KS and male controls when inves-
tigating the expression of five of these 6 respective X-Y homologues (Fig. 4), with expression levels higher for KS 
than for male controls for four of these gen pairs (KDM5C/KDM5D, ZFX/ZFY, KDM6A/UTY, DDX3X/DDX3Y). 
No expression data were available for TXLNGY. For inactivated genes, we identified three DEGs between KS 
and male controls, of which one gene, AMOT, was downregulated in both KS contrasts (Fig. 4E, Supplementary 
Fig. S2). We found seven pseudoautosomal DEGs between KS and male controls (Fig. 4F). One gene (SLC25 A6) 
was upregulated in both contrasts (FDR < 0.05; absolute log fold change ≥0.3) (Supplementary Fig. S3).
Gene set enrichment analysis of the DEGs in both KS contrasts showed enrichment for terms related to viral 
immune response (Supplementary Table S9), whereas analysis of DEGs between KS and male controls revealed 
enrichment for biological terms related to viral immune response in addition to terms related to interferon and 
interleukin production and signaling pathways as well as neuron development, vasodilatation, Wnt-signaling and 
catenin transport (Supplementary Table S10).
www.nature.com/scientificreports/
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Aberrant noncoding RNA expression profile in Klinefelter syndrome. While protein coding genes 
account for approximately 60% of the gene set in the human genome, noncoding RNA genes (ncRNAs) account 
for the remaining 40%25. Our understanding of the biological function of ncRNA genes and their involvement 
in gene regulation and disease development is still premature. ncRNA genes such as XIST, TSIX and JPX are 
known to be involved in the X chromosome inactivation process26. However, evidence suggests that ncRNA 
genes may also be involved in neurodevelopment and cognition25 as well as being implicated in the pathogenesis 
of various diseases including neurodegenerative diseases25, diseases of the immune system27 and diabetes28. We 
therefore asked whether ncRNA genes could be involved in the pathogenesis of KS. Extending our analysis to 
autosomal ncRNA genes revealed a pattern where KS clustered with male controls, the same pattern as seen in 
the analysis of autosomal coding genes (Fig. 5A, Supplementary Fig. S7). However, a clear clustering between 
the three groups was seen for X chromosomal ncRNA genes (Fig. 5B, Supplementary Fig. S10) in contrast to the 
analysis of coding X chromosomal genes, where no clear clustering between groups were seen. We identified 23 
(six upregulated and 17 downregulated) differentially expressed autosomal ncRNA genes between KS and male 
controls (Supplementary Fig. S6), 797 (294 upregulated and 503 downregulated) between KS and female controls 
and 1,026 (355 upregulated and 671 downregulated) between male and female controls (FDR < 0.05; absolute 
log fold change ≥0.3) (Fig. 5C). Seven ncRNA genes were differentially expressed in both KS contrasts (Fig. 5C) 
with three upregulated and four downregulated compared to male controls and female controls (Supplementary 
Fig. S6). Regarding X chromosomal ncRNA genes, we found seven (all upregulated) differentially expressed 
Figure 3. KS are associated with altered expression of autosomal coding genes. (A) Multi-dimensional 
scaling plot based on the biological coefficient of variation of autosomal coding gene expression data between 
KS (green), male controls (blue) and female controls (orange). (B) Venn diagram of autosomal coding gene 
expression data with FDR < 0.05 and absolute log fold change ≥0.3. (C) Volcano plots of FDR against log fold 
change of differentially expressed autosomal coding genes. Orange dots are differentially expressed autosomal 
coding genes with FWER < 0.05 and absolute log fold change ≥0.3. Red line represents FWER = 0,05. (D) 
Manhattan plot of differentially expressed genes between KS and male controls (top) and KS and female 
controls (bottom). Red line represents FWER < 0.05.
www.nature.com/scientificreports/
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ncRNA genes between KS and male controls (JPX, XIST, TSIX, G088512, RP13-216E22.4, RP13-36G14.4, 
G087825) (Fig. 5E, Supplementary Fig. S8), 36 (14 upregulated, 22 downregulated) in KS and female controls 
(Supplementary Fig. S9), and 52 (18 upregulated, 34 downregulated) between male and female controls (FDR < 
Figure 4. KS are also associated with differentially expression of X chromosomal coding genes. (A) Multi-
dimensional scaling plot based on the biological coefficient of variation of X chromosomal coding gene 
expression data between KS (green), male controls (blue) and female controls (orange). (B) Venn diagram of X 
chromosomal coding gene expression data with FDR < 0.05 and absolute log fold change ≥0.3. (C) Ideogram 
of X chromosome with location of genes differentially expressed between KS and 47,XY. Colored dots correlate 
to the annotation of genes as either pseudoautosomal, escape, inactivated or X-Y pair. (D–F) Venn diagram 
of differentially expressed X chromosomal coding genes with FDR < 0.05 and absolute log fold change ≥0.3 
annotated as either escape (D), inactivated (E) or pseudoautosomal (F).
www.nature.com/scientificreports/
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0.05; absolute log fold change ≥0.3)(Fig. 5D). JPX was differentially expressed (upregulated) between both KS 
contrasts (Fig. 5F). No difference in the expression level of XIST and TSIX were found between KS and female 
controls (Fig. 5G,H).
Correlation between differentially expressed genes in KS. We conducted correlation analysis of the 
31 DEG between KS and male controls of which 16 were also differently expressed between KS and female con-
trols, to investigate which DEGs correlated within the KS group. We found a positive correlation between IF144 
vs. IF144L (rho = 0.967, p < 0.001), IF144 vs. IFFIFIT1 (rho = 0.950, p < 0.001), IF144 vs. RSAD2 (rho = 0.950, 
p < 0.001) and IF144L and HERC5 (rho = 0.967, p < 0.001).
Correlation between DNA methylation and gene expression. DNA methylation has been shown 
to play a role in mediating gene expression. We therefore correlated methylation levels with gene expression. 
For autosomal genes, the analysis was performed for the KS vs. male controls comparison (corresponding to 39 
Figure 5. Non-coding gene expression in KS. (A,B) Multi-dimensional scaling plots based on the biological 
coefficient of variation of autosomal non-coding gene expression data (A) and of X chromosomal non-coding 
gene expression data (B) between KS (green), male controls (blue) and female controls (orange). (C,D) Venn 
diagram of autosomal (C) and X chromosomal (D) non-coding gene expression data with FDR < 0.05 and 
absolute log fold change ≥0.3. (D) Ideogram of X chromosome with location of non-coding genes differentially 
expressed between KS and 47,XY. (F–H) Boxplots of expression values (CPM, counts per million) of JPX, TXIS, 
XIST.
www.nature.com/scientificreports/
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genes). For X chromosomal genes, the analysis was performed for the KS vs. female controls comparison (corre-
sponding to three genes). We found a moderate correlation for three autosomal genes (BOLA1, DDX43, ZBTB44) 
as well as one X chromosomal gene (KDM5C) (Supplementary Fig. S11, Table S11).
Overlap between differentially methylated positions and differentially expressed genes 
reported previously in KS. Supplementary Tablesso far performed DNA methylation profiling or gene 
expression profiling in KS (Supplementary Table S12). Only the study by Wan et al.14 examined DNA methyla-
tion on peripheral blood samples in KS using the Illumina Infinium 450 K array14 with 38 out of 96 autosomal 
DMPs (FDR < 0.05 and absolute delta-beta > 0.1) overlapping between KS and male controls (36 hypermeth-
ylated, 2 hypomethylated)(Supplementary Table S13). Further, when comparing DMPs common to both KS vs. 
male controls and KS vs. 46,XX, 10 DMPs overlapped (all hypermethylated), corresponding to 4 genes (SPEG, 
ZNF497, G3BP1, NSD1) (Supplementary Table S14). No X chromosomal DMPs between KS and female controls 
overlapped (FDR < 0.05 and delta-beta > 0.1). Viana et al.13 also performed DNA methylation profiling in brain 
tissue of one KS man compared to male and female controls using the Illumina Infinium 450 K array. None of 
the autosomal DMRs found to differ between KS and male controls in the study by Viana et al.13 overlapped with 
the autosomal DMPs differing between KS and male controls in our study and no overlap was seen between X 
chromosomal DMR found between KS and female controls and the X chromosomal DMPs between KS and 
female controls. In addition, Sharma et al.12 performed DNA methylation profiling in peripheral blood samples 
in KS using the Illumina Infinium 27 K array. Concerning autosomal differentially methylated genes, we identi-
fied overlap between 4 genes (all hypermethylated) (APOB, FIGNL1, H1F0, NUPL1) (Supplementary Table S15), 
whereas no overlap between X chromosomal genes were seen. No information regarding specific probe names 
were available from Sharma et al.13.
In addition, only few studies have performed gene expression profiling in KS (Supplementary Table S12, 
Fig. S12). When comparing the data from these studies with our data, only a very small overlap was seen for autoso-
mal DEGs (Supplementary Table S16), whereas more overlap was seen for X chromosomal DEGs (Supplementary 
Table S17). Concerning autosomal DEGs, DACT1 was reported to be upregulated in the study by Belling et al.15 as 
well as in our study, DOCK7 was found to be upregulated both by Zitmann et al.17 and in our study, PTGDR was 
found to be downregulated in our study, but upregulated in brain tissue in the study by Viana et al.13 and CAMP 
was found to be downregulated by Belling et al.15, but upregulated in brain tissue by Viana et al.13. When comparing 
DEGs of the X chromosomes between the studies several genes overlapped. Nine of the upregulated X chromosomal 
DEGs found in our study were reported to be upregulated by Belling et al.15 (AKAP17A, ASMTL, EIF1AX, EIF2S3, 
PPP2R3B, PRKX, SEPT6, SLC25A6, XIST). In addition, 5 of these genes (ASMTL, EIF1AX, EIF2S3, PRKX, SLC25A6) 
were found to be upregulated in Zitzmann et al.17, whereas only one (XIST) of these nine DEGs were upregulated 
according to Vawter et al.16, XIST were also found to be upregulated in Huang et al.20. Six other DEGs found in our 
study were also found to be upregulated in Zitzmann et al.17, (DDX3X, KDM5C, KDM6A, TXLNG, ZBED1, ZFX). 
ZFX was also found to be upregulated in Vawter et al.16. In a murine study, DDX3X, KDM5C and EIF2S3 was upreg-
ulated in brain tissue from 41,XXY mouse compared to the 40,XY mouse29.
Discussion
We showed that the methylome as well as the transcriptome of both autosomes and the X chromosome are altered 
in leucocytes from KS and exhibit a unique profile compared to both male and females with normal karyotype. 
In addition, we found evidence that the X chromosome inactivation process in KS, to some extent, is comparable 
to that seen in women, however with an X chromosomal gene expression profile more similar to 46,XY males. 
Finally, we point out several candidate genes, which may likely be involved in the KS phenotype (Fig. 6).
Our finding that KS was mainly associated with hypermethylation and to a lesser extent hypomethylation, are 
in agreement with earlier studies12–14. Interestingly, this predominant hypermethylation is diametrically opposite 
to our recent observations for Turner syndrome (45,X)30. These results could imply that a gain or loss of an X 
chromosome in humans cause epigenetic instability or alterations, which may be implicated in the phenotype 
seen in sex chromosome aneuploidies, through an effect on transcriptional or translational regulation. In support 
of this hypothesis, previous studies on cell lines found evidence that the presence of aberrant chromosome mate-
rial may cause epigenomic instability by changing the regulation of transcription31.
Comparing our methylation data with previous studies of DNA methylation in KS, we identified four over-
lapping autosomal DMPs and 1 X chromosomal DMP. These 5 genes included SPEG, G3BP1, NSD1, ZNF497 
and SHROOM2. However, based on the known functional roles of these genes, it is plausible that these methyl-
ation changes could be implicated in the phenotypic traits seen in KS such as delayed motor development32,33, 
decreased muscle strength34,35, cardiac abnormalities3,36, cognitive deficits37, and endothelial dysfunction38 
(Fig. 6). However, we found no evidence that the altered methylation of these genes were accompanied by dif-
ferences in gene expression levels in our study. The missing correlation with gene expression seen in our study 
could possibly relate to the fact that the link between DNA methylation and gene expression is more complex. 
Thus, the biological function of the altered methylome seen in KS is not clear. In support of a biological function 
of these DNA methylation alteration, gene set enrichment analysis of our autosomal DMPs revealed enrichment 
for terms highly relevant to the phenotype seen in KS, supporting the hypothesis that the aberrant DNA meth-
ylation profile seen in KS is implicated in the phenotype. However, one could also speculate that the epigenetic 
alterations may simply be an epigenetic fingerprint of having an extra X-chromosome, without having biological 
functions in relation to gene expression and comorbidities. Another possibility is that these epigenetic alterations 
may be needed for survival of fetuses with KS. In light of our recently published data on Turner syndrome (45,X), 
we believe that the gain and loss of an X chromosomes is responsible for the changes seen in the methylome of 
individuals with sex chromosome aneuploidies, although the exact biological impact of the changes remain a 
question for future research.
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Regarding the altered transcriptome seen in KS, gene set enrichment analysis suggest that KS may be associ-
ated with a deregulation of the immune system, Wnt-signaling pathway and neuron development. Interestingly, 
KS patients have an increased prevalence of infections and autoimmune diseases3,39, which may explain why the 
biological terms ‘defense to virus’ was the most significantly enriched term in addition to enrichment for terms 
related to interferon and interleukin signaling. In agreement with this, Belling et al. also reported enrichment for 
biological terms such as immune response and several immune-related pathways15. Another enriched term was 
“Wnt-signaling”. Several studies have demonstrated a link between deregulated wnt-signaling and human disease 
such as cancer, embryonic development and malformation, bone density, diabetes and vasculogenesis, and there 
is evidence that Wnt-signaling is involved in synaptic activity and plasticity and may be crucial for normal learn-
ing and memory. Thus, deregulated Wnt-signaling may be involved in the cognitive deficits in learning and mem-
ory seen in the majority of KS patients37 as well as being involved in other phenotypic traits such as osteoporosis, 
diabetes, vascular comorbidities and congenital malformations (Fig. 6).
Aberrant expression of escape genes has been suggested to be associated with and likely causative for the 
phenotype in KS. We identified ten escape genes (all upregulated) in KS compared to male controls, with only 
KDM5C differentially expressed between KS and female controls. KDM5C is thought to play a role in cognitive 
function and has been suggested as a candidate gene involved in the neurocognitive phenotype seen in KS40. 
Seven of the ten escape genes (KDM5C, EIF1AX, KDM6A, DDX3X, TXLNG, PRKX, EIF2S3) were also upreg-
ulated in KS compared to male controls in the study by Zitzmann et al.17. In addition, Belling et al.15 also found 
EIF1AX, EIF2S3 and PRKX upregulated in KS compared to male controls. However, when we took into account 
the Y homolog of 5 of our 10 differentially expressed escape genes (KDM5C/D, EIF1AX/EIF1AY, ZFX/XFY, 
KDM6A/UTY, DDX3X/DDX3Y), no difference in expression values were seen between KS and male controls. 
Cognitive dysfunction
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Figure 6. The Figure illustrate tentative candidate genes involved in different phenotypic traits of Klinefelter 
syndrome. The model should be seen as a hypothesis generating model. Gene names written in red are genes, 
which are found to be differentially methylated in KS, whereas gene names written in blue hare genes found to 
be differentially expressed in KS.
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The Y homologs were not taken into account in the studies by Belling et al.15. and Zitzmann et al.17. Thus, based 
on the rather limited available published studies performing gene expression profiling, the demonstrated altered 
expression of the TXLNG and EIF2S3 genes, likely contribute to the disease pathogenesis of KS. TXLNG may 
regulate bone mass density and is an interesting candidate gene of the decreased bone mass and the increased 
risk of developing osteoporosis in KS. EIF2S3 has been linked to X linked mental retardation, hypogonadism, 
obesity, microcephaly and epilepsy and among its related pathways are regulation of lipid metabolism and insulin. 
Further, it has been suggested to contribute to spermatogenesis. As such, these 2 genes may be implicated in sev-
eral of the phenotypic traits seen in KS, such as osteoporosis34, dyslipidemia17,41, diabetes41, obesity41, decreased 
total brain volume42, hypogonadism and azoospermia10 (Fig. 6).
In addition to genes annotated as escape genes, pseudoautosomal genes have also been characterized as prime 
candicates of the phenotype in KS, since these genes are expressed from three loci in KS. We found SLC25A6 to be 
significantly upregulated in KS in agreement with Zitzmann et al.17 and Belling et al.15 SLC25A6 is involved in cal-
cium signaling pathway and metabolism. Interestingly, Zitzmann et al. found that higher expression of SLC25A6 
was correlated with shorter QTc. Thus, overexpression of SLC25A6 may be part of the molecular mechanism 
behind short QTc interval in KS patients43 (Fig. 6). The other pseudoautosomal genes found to be upregulated in 
KS compared to male controls in our study, had an expression level similar to female controls. It is possible that 
this female pattern of expression in KS contribute to the phenotype, given that biological processes in males may 
not function properly with a female gene dose. In agreement with our data, previously published studies have also 
found ASTML, AKAP17A, PPP2R3B and ZBED1 upregulated in KS15,17,19. ASTML may have methyltransferase 
activity. Both ZBED1 and PPP2R3B may have a role in the regulation of cell growth and division, and AKAP17A 
has been associated with chronic tic disorder. Thus, the alterations in gene expression of these pseudoautosomal 
genes, may indicate that KS is associated with disturbances in basic biological pathways related to cell growth and 
in mRNA splicing as well as an increased susceptibility to develop tic disorders (Fig. 6). Interestingly, tics have 
been described in case reports of KS44–46.
In cells with more than one X chromosome, additional X chromosomes are inactivated6. X chromosome 
inactivation is regulated by the X inactivation center, which includes the non-protein coding gene XIST, essential 
for the inactivation process47. Evidence suggest that the regulation of XIST exhibit species-specific differences, 
with TSIX and JPS being involved in the regulation of Xist in mouse but not in humans48. Our data showed that 
expression values of XIST in KS were equal to that seen in females, which is in agreement with earlier studies, 
reporting the same degree of XIST methylation in KS and females, and are further supported by results from 
studies of male 41,XXY mice49. This indicates that the inactivation of the supernumerary X chromosome in KS 
could be comparable to that seen in women. However, our data also revealed several genes annotated as inacti-
vated, which are differentially expressed between KS and females (n = 22) as well as between males and females 
(n = 29) which may indicate that the X inactivation is not equal to that seen in females, but is modified towards an 
expression pattern similar to that seen in males, which were further supported by our findings of only 3 differen-
tially expressed inactivated genes between KS and males. One of the inactivated genes, AMOT was downregulated 
compared to both female controls and male controls. AMOT is expressed in endothelial cells of capillaries and 
plays a role in endothelial cell-cell junctions. AMOT could thus be involved in the endothelial dysfunction seen 
in KS38, which may be part of the pathogenesis underlying comorbidities in KS, such as hypertension, diabetes, 
atherosclerosis and erectile dysfunction. Interestingly, we found a significantly higher expression of JPX in KS 
compared to both male and female controls and a significantly higher expression of TSIX compared to male con-
trols but not female controls. We speculated if these findings could be related to the X chromosome inactivation 
process in KS, however further studies are needed to investigate these hypothesis.
We found several non-coding genes to be differentially expressed in KS compared to both male controls and 
female controls, including many with unknown function. The biological implications of the aberrant expression 
of these non-coding genes remain to be elucidated. Interestingly, some of the differentially expressed X chromo-
somal non-coding genes were located in close proximity to the X chromosome inactivation center, or in close 
proximity to known escape genes (KDM5C, ZFX and EIF2S3)50, indicating that these non-coding genes could be 
involved in the regulation of the X chromosome inactivation and the expression of escape genes, which has to be 
further investigated in future studies.
The limitations of this study include the lack of a validation cohort. Comparisons of our results with previ-
ously published studies in this field revealed some overlap. The discrepancy in results, between studies provid-
ing DNA methylation and gene expression profiling in KS, may relate to a different co-morbidity profile and to 
different methods and arrays. Furthermore, our study was restricted to the tissue specific DNA methylation and 
RNA expression in leucocytes from peripheral blood samples. Thus to further establish the impact of DNA meth-
ylation and gene expression on the phenotype in KS, future studies should include DNA methylation and gene 
expression profiling in different target tissue types relevant for the phenotype, such as heart, brain, testis, muscle, 
and fat tissue. In addition, studies including analysis of microRNA should be performed as these RNAs function 
as regulators of gene expression and a recently published study found evidence that the expression of microRNA 
may be changed in KS as well51.
In conclusion, our results demonstrate a unique epigenetic and genetic landscape in KS involving both the 
X chromosome and the autosomal chromosomes, with few correlations between methylation values and gene 
expression. We found several candidate genes, which could be involved in the phenotype seen in KS. In addition, 
we found differentially expressed X chromosomal ncRNA genes located in close aproximity to the X inactivation 
center or to escape genes, suggesting a role of these ncRNA genes in the X chromosome inactivation in KS and in 
the regulation of some of the escape genes. Lastly, our results suggest that the Wnt-signaling pathway and immune 
system may be deregulated in KS.
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Methods
Sample inclusion. Participants included 67 KS patients with standard KS karyotype (mean age ± SD: 
36.4 ± 10.0 years) and 67 age-matched male controls (46,XY) (mean age ± SD: 36.3 ± 9.71 years) in addition to 33 
female controls female controls (46,XX) (mean age ± SD: 45.0 ± 10.3 years) from a previous study of Turner syn-
drome (Clinical Trial NCT01678261). DNA methylation profiling was performed on peripheral blood samples 
from all participants. Gene expression profiling were performed on peripheral blood samples from a subset of 
participants including 9 KS (mean age ± SD: 36.0 ± 6.78 years), 9 male controls (mean age ± SD: 36.2 ± 7.14 years) 
and 13 female controls (mean age ± SD: 35.0 ± 7.34). All participants provided informed consent. The study was 
approved by The Danish Data Protection Agency and the local ethics committee (Region Midjylland, Denmark 
number M-20080238, and all clinical investigations were conducted according to the principles expressed in the 
Declaration of Helsinki. This research has been registered at ClinicalTrials.gov (Clinical trial NCT00999310).
Sample preparation. Illumina 450 K methylation assay. EDTA treated peripheral blood samples from 
participants were stored immediately until use at −80 °C. Genomic DNA was extracted using QIAmp® Mini 
Kit (Qiagen, Germany). For each sample, 1 μg of genomic DNA was bisulfite-converted using Zymo EZ DNA 
methylation Kit. The methylation level was measured using the Infinium® HumanMethylation450 Beadchip Kit 
(Illumina, Inc.) at Aros Applied Biotechnology A/S.
Illumina 450 K microarray data preprocessing. The R package minfi were used to analyze data52. Detection 
p-values were calculated to identify failed positions with a p-value cut-off >0.01. Probes that failed in more 
than 20% of the samples were removed (n = 183). Individual positions were removed at the specified cut-off. No 
samples had a proportion of failed probes exceeding 1% or a median intensity below 11. Raw data was normal-
ized implementing the preprocessing defaults of Genome Studio® with background normalization and control 
normalization. Next, we applied subset-quantile-within-array-normalization correcting for technical differences 
between Infinium type I and II assay design allowing both within-array and between-sample normalization. 
Cross reactive probes (n = 29,532), probes with SNPs documented in the C or G of the target (n = 18,247), and 
probes on the sex chromosomes (n = 11,642) were excluded, leaving 414,960 probes. Methylation values where 












Multidimensional scaling plots were evaluated to identify clusters of samples behaving differently than expected. 
Finally, probes were annotated to the human genome version 19 using the enhanced Illumina annotation method 
developed by Price et al.54.
Estimate differential cell counts. To account for differences in cell composition, Minfi’s estimateCellCounts was 
used for returning the relative proportions of CD4+ and CD8+ T-cells, natural killer cells, monocytes, granulo-
cytes, and B-cells in each sample55.
Identifying differentially methylated positions (DMPs). To identify positions where methylation is associated 
with the karyotype we fitted a linear model, which utilizes a generalized least squares model (lmFit of R-package 
Limma) allowing for missing values. Significance was evaluated using F-test. The sample variances were esti-
mated using an empirical Bayes approach with shrinkage towards the means. A Bonferroni adjusted family wise 
error rate (FWER) below 0.05 was considered significant. The model was applied without and subsequently with 
adjustment for the estimated relative cell proportions (CD4+ and CD8+ T-cells, natural killer cells, monocytes, 
granulocytes, and B-cells) as well as age. Since small changes in M-values might be of spurious biological signif-
icance we added a delta M-value-threshold excluding all DMPs with a |delta-M-value| < 1. Chromosomal and 
gene-centric-region enrichment analysis was done applying hypergeometric testing to the KS vs. male controls 
comparison in order to identify if any chromosome or gene centric region was enriched for methylation changes.
Repetitive elements. We used annotation from Price et al.54 to identify autosomal probes in repetitive regions that 
did not cross- react, such that we could compare the methylation level at these regions between KS and male con-
trols. We clustered probes if they were on the same chromosome and separated by less than 500 base pairs defining 
in total 1403 regions in addition to 19465 Illumina probes hybridizing to repetitive elements. In addition, we pre-
formed analysis to investigate if the number of DMPs in repetitive elements were more than expected per chance.
Identifying differentially methylated regions (DMRs). DMRcate was used to identify autosomal as well as X chro-
mosomal DMRs56. DMRcate identifies and ranks the most differentially methylated regions across the genome 
based on kernel smoothing of the differential methylation signal. The model performs well on small sample sizes 
and builds on the well-established limma package57, allowing us to incorporate estimated cell proportions as 
covariates. A Benjamini-Hochberg corrected false discovery rate (FDR) < 0.05 with a |delta-M-value| > 0.1 was 
considered significant. Following FDR-correction, regions were agglomerated from groups of significant probes 
with a distance of less than 1000 base pairs to the next significant probe. Only DMRs with two or more probes 
are reported.
Functional annotation based on DNA methylation data. DMPs were annotated to the human genome version 
19. DMPs common to both the KS vs. male controls and KS vs. female controls adjusted comparison with a 
FWER < 0.05 and absolute delta-M-value > 0.5. Enrichment of functional terms among associated genes were 
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analysed with DAVID (The Database for Annotation, Visualization and Integrated Discovery). A background 
list composed of genes corresponding to the 414,960 probes left for downstream analysis were entered. The data-
base performs a biological module-centric analysis viewing functionally related genes together as a unit in order 
to identify the most overrepresented biological terms associated with a given gene list. The DAVID functional 
annotation clustering measures the relationship among the annotation terms on the basis of the degree of their 
co-association with genes within the entered gene list to cluster into functional annotation groups. Terms with 
Fisher’s exact p-value < 0.05 are reported.
DMRs with a FWER < 0.05 and absolute delta-M-value > 0.1 were annotated using GREAT (The Genomic 
Regions Enrichment of Annotations Tool). DMRs were mapped to genes, assigned a regulatory domain extended 
10 kb proximal and 3 kb downstream of the transcription start site with a distal extension of 150 kb. We included 
the curated Regulatory Domain option.
RNA preparation. Blood samples were drawn using RNApax gene tubes and placed 2 hours at room tempera-
ture, sequentially stored overnight at −21 degrees before storage at −80 degrees.
RNA-Seq library construction and sequencing. Whole transcriptome, strand-specific RNA-Seq libraries were 
prepared from total-RNA using the Ribo-Zero Globin technology (Epicentre, an Illumina company) for deple-
tion of rRNA and globin mRNA followed by library preparation using the ScriptSeq technology (Epicentre, 
an Illumina company). Depletion and library preparation were automated on a Sciclone NGS (Caliper, Perkin 
Elmer) liquid handling robot. The total-RNA (1.7 µg per sample) was subjected to Baseline-ZERO DNase prior 
to depletion. Total-RNA was purified using Agencourt RNAClean XP Beads before and after DNase treatment 
followed by on-chip electrophoresis on a LabChip GX(Caliper, Perkin Elmer) and by UV measurements on a 
NanoQuant(Tecan). Cytoplasmic and mitochondrial rRNA as well as globin mRNA were removed from 400 ng 
DNAse treated total RNA using the Ribo-Zero Globin Gold Kit (Human/Mouse/Rat, Epicentre, an Illumina 
company) following the manufacturer’s instructions and quality of the depleted RNA was estimated on a LabChip 
GX (Caliper, Perkin Elmer). Synthesis of directional RNA-Seq libraries were conducted using the ScriptSeq v2 
kit (Epicentre, an Illumina company) following the recommended procedure, and the qualities of the RNA-Seq 
libraries were estimated by on-chip electrophoresis (HS Chip, LabChip GX, Caliper, Perkin Elmer) of a 1 µL 
sample. The DNA concentrations of the libraries were estimated using the KAPA Library Quantification Kit 
(Kapa Biosystems). The RNA-Seq libraries were multiplexed paired-end sequenced on an Illumina HiSeq. 2000 
(100 + 6 + 100 bp) or on an Illumina NextSeq (75 + 6 + 75 bp).
RNA-Seq analysis. Paired de-multiplexed fastq files were generated using CASAVA software (Illumina) 
and initial quality control was performed using FastQC. Adapter trimming was conducted using the GATK 
ReadAdaptorTrimmer tool followed by mapping to the human genome (hg19) using Tophat58. The gene expres-
sion were performed on two iterations, first on protein coding genes extracted from gencode v15 and non-coding 
transripts were extracted from gencode v19 and supplements from the mirbase, mitranscriptome, rfam, snorn-
abase, tjumirna and trnascanse databases. HTSeq-count (union method) was applied to produce raw counts 
submitted for analysis in R using edgeR59. All non-informative features were removed. Filtering was done by 
removing features with less than one counts per million (cpm) in 9 samples leaving 11407 autosomale coding 
genes, 6380 non-coding autosomale RNAs, 424 X chromsomale coding genes, 231 non-coding X chromosomal 
RNAs for downstream analysis60. A generalized linear model was fitted yielding an overall p-value. Secondly, 
p-values and log fold changes (LogFC) were retrieved from the individual comparison of KS vs. male controls, KS 
vs. female controls and male controls vs. female controls. Genes from the comparison KS vs. male controls were 
submitted to DAVID for functional annotation pathways. Categories with a Fisher´s exact test p-value < 0.05 were 
retrieved. The FDR was controlled using the Benjamini-Hochberg´s procedure. Information on X-Y homologs 
was adapted from Bellot et al.21 and HGNC gene symbols and ensemble gene IDs were retrieved. Fragments 
Per Kilobase of Exon values (FPKM) of the X-Y pairs were calculated and summed. Differential expression was 
assessed with Kruskal-Wallis test and Mann-Whitney U-test. We used the gene annotation by Bellott et al.21.
Analysis software. Statistical computations were performed using R 3.1.0 (R Foundation for Statistical 
Computing, Vienna, Austria) with Bioconductor 3.061. DNA methylation data was assessed using the minfi52, 
DMRcate56 and Limma57 package, and RNAseq data using edgeR. Graphics were made using the basic R func-
tions, ggbio, Gviz, DEseq60, DEXSeq and ggplot262. The package knitr was used for data documentation. Ideogram 
were created using Ideographica63.
Accession Numbers. Sequence data has been deposited at the European Genome-phenome Archive (EGA), 
which is hosted by the EBI and the CRG, under accession numbers EGAS00001002190 and EGAS00001002797. 
Further information about EGA can be found on https://ega-archive.org “The European Genome-phenome 
Archive of human data consented for biomedical research.
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